BRA
ALXN

Bender Robert & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Bender Robert & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,373
Closed -$4.11M – 51
2021
Q2 		$4.11M Sell
22,373
-233
-1% -$40K 1.17% 20
2021
Q1 		$3.46M Sell
22,606
-255
-1% -$39.4K 1.11% 22
2020
Q4 		$3.57M Buy
22,861
+445
+2% +$57.2K 1.14% 23
2020
Q3 		$2.56M Sell
22,416
-387
-2% -$41.8K 0.92% 24
2020
Q2 		$2.56M Sell
22,803
-1,278
-5% -$136K 1.01% 24
2020
Q1 		$2.16M Sell
24,081
-2,610
-10% -$256K 1.15% 22
2019
Q4 		$2.89M Sell
26,691
-614
-2% -$65.7K 1.3% 23
2019
Q3 		$2.67M Sell
27,305
-190
-0.7% -$21.4K 1.34% 24
2019
Q2 		$3.15M Sell
27,495
-4,168
-13% -$537K 1.5% 21
2019
Q1 		$4.28M Sell
31,663
-737
-2% -$91.6K 2.1% 19
2018
Q4 		$3.15M Sell
32,400
-213
-0.7% -$25.2K 1.82% 21
2018
Q3 		$4.53M Sell
32,613
-151
-0.5% -$18.9K 2.06% 19
2018
Q2 		$4.07M Buy
32,764
+105
+0.3% +$12.3K 2.13% 18
2018
Q1 		$3.64M Sell
32,659
-214
-0.7% -$25.6K 2.02% 20
2017
Q4 		$3.93M Buy
32,873
+430
+1% +$52.4K 2.18% 21
2017
Q3 		$4.55M Sell
32,443
-17
-0.1% -$2.31K 2.62% 17
2017
Q2 		$3.95M Buy
32,460
+451
+1% +$52.5K 2.42% 19
2017
Q1 		$3.88M Sell
32,009
-1,340
-4% -$173K 2.5% 18
2016
Q4 		$4.08M Sell
33,349
-634
-2% -$77.6K 2.89% 15
2016
Q3 		$4.16M Sell
33,983
-215
-0.6% -$27.7K 2.75% 15
2016
Q2 		$3.99M Sell
34,198
-511
-1% -$72.5K 2.82% 12
2016
Q1 		$4.83M Sell
34,709
-1,045
-3% -$153K 3.27% 12
2015
Q4 		$6.82M Sell
35,754
-335
-0.9% -$58.5K 4.37% 7
2015
Q3 		$5.64M Sell
36,089
-820
-2% -$150K 3.82% 8
2015
Q2 		$6.67M Buy
36,909
+191
+0.5% +$33K 3.96% 7
2015
Q1 		$6.36M Buy
36,718
+126
+0.3% +$22.8K 3.71% 12
2014
Q4 		$6.77M Sell
36,592
-53
-0.1% -$9.82K 4.43% 7
2014
Q3 		$6.08M Sell
36,645
-303
-0.8% -$49.8K 4.23% 8
2014
Q2 		$5.77M Sell
36,948
-290
-0.8% -$45.8K 4.08% 8
2014
Q1 		$5.67K Sell
37,238
-847
-2% -$135K 3.8% 10
2013
Q4 		$2.06M Sell
38,085
-136
-0.4% -$16.3K 1.55% 24
2013
Q3 		$4.44M Sell
38,221
-127
-0.3% -$13.9K 3.48% 10
2013
Q2 		$3.54M Buy
+38,348
New +$3.7M 3.04% 12

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Bender Robert & Associates's ALXN Position: Q3 2021 in Review

Bender Robert & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 22,373 shares — an estimated $4.11M sold.

Bender Robert & Associates first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $6.82M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bender Robert & Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bender Robert & Associates sold 22,373 Alexion Pharmaceuticals shares in Q3 2021, an estimated $4.11M.
  • Bender Robert & Associates first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Bender Robert & Associates's Alexion Pharmaceuticals position peaked at $6.82M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bender Robert & Associates's 13F filing for Q3 2021, filed 3 Nov 2021.